Citi upgrades CSL (ASX:CSL) share price to buy rating on Vifor Pharma deal

CSL has found a new bull…

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price will be one to watch when it returns from its trading halt.

This follows the release of a broker note which is tipping the biotherapeutics company's shares to shoot higher.

What's happening?

In case you're not aware, at present the CSL share price is paused while the company raises funds to make a major acquisition.

CSL has signed an agreement to acquire Swiss biotech giant Vifor Pharma for US$12.3 billion (A$17.2 billion) in cash. This will be funded through a combination of a fully underwritten US$4.5 billion placement, a US$534 million share purchase plan, new debt, and existing cash reserves.

Management notes that the deal expands its leadership across an attractive portfolio focused on Renal Disease and Iron Deficiency. Furthermore, it has a high quality pipeline and complements CSL's existing therapeutic focus areas including Haematology, Thrombosis, Cardiovascular, and Transplant.

What did the broker say about the CSL share price?

The team at Citi is very positive on the acquisition. So much so, in response the broker has upgraded CSL's shares to a buy rating with an improved price target of $340.00.

Based on the current CSL share price, this implies potential upside of 14% over the next 12 months.

Citi commented: "CSL has announced that the acquisition of Vifor Pharma – it is acquiring the company at CHF165.5 (US$179.25), a ~65% premium to where the stock was trading pre bid discussion and a ~37% premium to the three-month VWAP. We calculate the acquisition to be ~9% accretive to NPATA per share (NPAT before acquisition-related amortization) – a proxy for cash flow. Including amortization, the transaction is expected to be "modestly accretive" to EPS."

"CSL is acquiring Vifor Pharma at roughly ~14x FY23 EBITDA (including the full run rate of US$75m in cost synergies). Time will tell if CSL has paid a full price given that the revenue is currently subdued because of the pandemic, and several new products are yet to launch, but the transaction should be ROIC dilutive in FY23. CSL's management team presented the transaction as being strategically aligned with the existing business," it added.

The CSL share price is up 4% in 2021.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man looking at his laptop and thinking.
Broker Notes

Up 17% in 2025, how much more upside does Macquarie tip for Metcash shares?

Following Tuesday’s merger and earnings news, Macquarie changed its rating for Metcash shares.

Read more »

Female ASX travel shares investor with surprised expression drinks a cup of tea while reading the newspaper at her desk
Broker Notes

Macquarie is tipping this top ASX 200 share to deliver a 35% return

The leading broker sees major upside potential for this growing company.

Read more »

Business man at desk looking out window with his arms behind his head at a view of the city and stock trends overlay.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Sell buy and hold on a digital screen with a man pointing at the sell square.
Broker Notes

Take your profits and run! Brokers say sell these 3 ASX 200 shares

Experts say these ASX 200 stocks are trading at high share prices with limited upside potential from here.

Read more »

Person handing out $50 notes, symbolising ex-dividend date.
Broker Notes

Where to invest $20,000 into ASX 200 shares

Brokers think these shares could be top picks for Aussie investors.

Read more »

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »